WuXi AppTec expands global manufacturing network across US, Europe and Asia

WuXi AppTec is adding manufacturing capacity in the U.S., Switzerland, Singapore and China as drugmakers look for more regional options and supply-chain resilience. The expansion is designed to keep one quality system across sites while giving customers more flexibility on where development and production happen. Why it matters: - Pharmaceutical companies are asking for more geographic flexibility in development and manufacturing. - WuXi AppTec is expanding capacity across multiple regions to give customers more site choices without changing quality standards. - The buildout supports demand in both established drug areas and newer modalities that need specialized manufacturing. What happened: - WuXi AppTec is expanding manufacturing capabilities across the United States, Europe and Asia. - The latest investments include major projects in the U.S., Switzerland, Singapore and China. - The expansion covers both drug substance and drug product production. - The company framed the strategy in a recent interview with Pharma Manufacturing. - Dr. Minzhang Chen, WuXi AppTec co-CEO, said the company is responding to customer demand for manufacturing flexibility. The details: - WuXi AppTec operates under a single quality system that lets customers choose manufacturing sites based on their development and commercialization plans. - The company says that model is designed to maintain consistent operational and regulatory standards across regions. - The new Middletown, Delaware facility will become WuXi AppTec’s largest U.S. site. - The Delaware site spans 1.74 million square feet and is built for drug product manufacturing for the North American market. - Oral solid dosage manufacturing is expected to start in Q4 2026. - Sterile and injectable manufacturing is expected to start in Q4 2027. - In Couvet, Switzerland, WuXi AppTec is expanding its site to meet rising commercial demand. - A new PSD-4 spray dryer at the Swiss site is expected to begin operating later this year. - Future expansion in Couvet includes parenteral manufacturing and lipid nanoparticle capabilities. - In Singapore, Phase I operations are expected to begin in 2027. - The Singapore site will add API manufacturing for small molecules, oligonucleotides, peptides and conjugates. - In China, two new small molecule API plants at the Taixing site are expected to become operational this year. - Two additional Taixing plants for oligonucleotide, peptide and PMO production are scheduled to begin operations in 2027. - WuXi AppTec says demand is strong across oncology, cardiovascular and metabolic diseases, infectious diseases, central nervous system disorders and rare diseases. - The company also points to rising demand for specialized manufacturing tied to peptides, oligonucleotides and TPDs. Between the lines: - The expansion reflects a broader industry shift toward dual goals: more regional manufacturing options and tighter supply-chain resilience. - WuXi AppTec is positioning its CRDMO model as a way to serve customers from discovery through commercial manufacturing while keeping operations coordinated globally. - The focus on multiple regions suggests customers are balancing local supply preferences with global capacity needs. What’s next: - The Delaware site is set to start oral solid dosage production in Q4 2026. - Sterile and injectable manufacturing at the Delaware site is scheduled for Q4 2027. - The PSD-4 spray dryer in Switzerland is expected to come online later this year. - Singapore Phase I operations are expected in 2027. - The remaining Taixing plants are scheduled to start in 2027. - WuXi AppTec’s broader network expansion will continue as customer demand shifts across modalities and regions. The bottom line: - WuXi AppTec is building a distributed manufacturing footprint that lets customers choose where work happens without giving up a unified quality system.